Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tan A Ince

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2018
Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like CellsFiona Simpkins, Kibeom Jang, Hyunho Yoon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2015
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian CancerKarina E Hew, Philip C Miller, Dorraya El-Ashry, et al.
The Journal of Clinical Investigation|January 28, 2014
Taxonomy of breast cancer based on normal cell phenotype predicts outcomeSandro Santagata, Ankita Thakkar, Ayse Ergonul, et al.
Nature Communications|June 17, 2024
C-terminally phosphorylated p27 activates self-renewal driver genes to program cancer stem cell expansion, mammary hyperplasia and cancerSeyedeh Fatemeh Razavipour, Hyunho Yoon, Kibeom Jang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 20, 2026
A Metal-Free Carbon Monoxide Prodrug Suppresses Metastasis of Pancreatic and Breast CancerTiantian Zhang, Xiang Chen, Xiaoxiao Yang, et al.
Plos One|December 5, 2013
Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomesMelissa A Merritt, Stefan Bentink, Matthew Schwede, et al.
Stem Cells (Dayton, Ohio)|February 13, 2013
Induced pluripotent stem cells with a mitochondrial DNA deletionAnne B C Cherry, Katelyn E Gagne, Erin M McLoughlin, et al.
The Journal of Clinical Investigation|April 26, 2014
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearanceRachel A Davidowitz, Laura M Selfors, Marcin P Iwanicki, et al.
Ebiomedicine|September 14, 2020
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerGoldie Y L Lui, Reid Shaw, Franz X Schaub, et al.
EMBO Reports|September 13, 2024
HPV-YAP1 oncogenic alliance drives malignant transformation of fallopian tube epithelial cellsChunbo He, Xiangmin Lv, Jiyuan Liu, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2018
Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like CellsFiona Simpkins, Kibeom Jang, Hyunho Yoon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2015
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian CancerKarina E Hew, Philip C Miller, Dorraya El-Ashry, et al.
The Journal of Clinical Investigation|January 28, 2014
Taxonomy of breast cancer based on normal cell phenotype predicts outcomeSandro Santagata, Ankita Thakkar, Ayse Ergonul, et al.
Nature Communications|June 17, 2024
C-terminally phosphorylated p27 activates self-renewal driver genes to program cancer stem cell expansion, mammary hyperplasia and cancerSeyedeh Fatemeh Razavipour, Hyunho Yoon, Kibeom Jang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 20, 2026
A Metal-Free Carbon Monoxide Prodrug Suppresses Metastasis of Pancreatic and Breast CancerTiantian Zhang, Xiang Chen, Xiaoxiao Yang, et al.
Plos One|December 5, 2013
Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomesMelissa A Merritt, Stefan Bentink, Matthew Schwede, et al.
Stem Cells (Dayton, Ohio)|February 13, 2013
Induced pluripotent stem cells with a mitochondrial DNA deletionAnne B C Cherry, Katelyn E Gagne, Erin M McLoughlin, et al.
The Journal of Clinical Investigation|April 26, 2014
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearanceRachel A Davidowitz, Laura M Selfors, Marcin P Iwanicki, et al.
Ebiomedicine|September 14, 2020
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerGoldie Y L Lui, Reid Shaw, Franz X Schaub, et al.
EMBO Reports|September 13, 2024
HPV-YAP1 oncogenic alliance drives malignant transformation of fallopian tube epithelial cellsChunbo He, Xiangmin Lv, Jiyuan Liu, et al.
Pageof 7